Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] The company is in the manufacturing and marketing of herbal products. However, the super profits shown by it for FY23 raise eyebrows and appear to be a window dressing. The asking price based on its super earnings appears to be lucrative at 8.4 P/E, but the sustainability of such performance going forward is a major concern. Though this issue is prima facie lucratively priced, there is no harm in skipping it. Read detail review...
Shelter Pharma Limited peer comparison with similar listed entities. () (As on March 31, 2022)
| Company Name | EPS (Rs) | NAV (per share) (Rs) | P/E (x) | RoNW (%) |
|---|---|---|---|---|
| EPS Basic | ||||
| Shelter Pharma Limited | 2.66 | 11.37 | 19.55 | 23.39 |
| Dabur India Limited | 8.11 | 33.31 | 64.85 | 24.43 |
| Emami Limited | 19.15 | 47.39 | 18.64 | 40.78 |
Notes:
Shelter Pharma IPO Reviews, analysis and views by popular members. Read Shelter Pharma Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
RHP